ID   M21R
AC   CVCL_A1FB
SY   M21-R
DR   cancercelllines; CVCL_A1FB
DR   Cosmic; 2757121
DR   Wikidata; Q102114490
RX   PubMed=24732172;
CC   Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24732172).
CC   Derived from site: Metastatic; Not specified.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D031 ! M21
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 19-12-24; Version: 7
//
RX   PubMed=24732172; DOI=10.18632/oncotarget.1878; PMCID=PMC4039118;
RA   Sabbatino F., Wang Y.-Y., Wang X.-H., Flaherty K.T., Yu L., Pepin D.,
RA   Scognamiglio G., Pepe S., Kirkwood J.M., Cooper Z.A., Frederick D.T.,
RA   Wargo J.A., Ferrone S., Ferrone C.R.;
RT   "PDGFRalpha up-regulation mediated by sonic hedgehog pathway
RT   activation leads to BRAF inhibitor resistance in melanoma cells with
RT   BRAF mutation.";
RL   Oncotarget 5:1926-1941(2014).
//